BCAX Stock Forecast: Bicara Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Bicara Therapeutics, Inc. is $35. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Bicara Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (57): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BCAX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BCAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 8 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $42 → $36 |
| 10 Nov 2026 | BTIG | Maintains | Buy | $39 → $37 |
| 10 Nov 2026 | Morgan Stanley | Maintains | Overweight | $41 → $30 |
| 10 Nov 2026 | Stifel | Maintains | Buy | $45 → $43 |
| 30 Oct 2026 | Goldman Sachs | Downgrade | Sell | $20 → $8.00 |
| 29 Oct 2026 | Wedbush | Maintains | Outperform | $33 → $24 |
| 19 Oct 2026 | BTIG | Reiterates | Buy | $39 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | $35 |
| 12 Aug 2026 | BTIG | Maintains | Buy | $28 → $39 |
| 12 Aug 2026 | Goldman Sachs | Maintains | Neutral | $18 → $20 |
| 12 Aug 2026 | Mizuho | Maintains | Neutral | $18 → $20 |
| 12 Aug 2026 | Morgan Stanley | Maintains | Overweight | $37 → $39 |
| 12 Aug 2026 | Wedbush | Maintains | Outperform | $30 → $33 |
| 12 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $16 → $23 |
| 12 May 2026 | Goldman Sachs | Maintains | Neutral | $16 → $18 |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | $36 → $37 |
| 11 May 2026 | Guggenheim | Initiates | Buy | $42 |
| 31 Mar 2026 | Citizens | Reiterates | Market Outperform | — |
| 31 Mar 2026 | Goldman Sachs | Maintains | Neutral | — |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BCAX.
This page is one stock. Monday covers all of them.
BCAX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BCAX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Bicara Therapeutics, Inc. returned −47.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BCAX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.4×
- EV / EBITDA
- —
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −54.2%
- Return on assets
- −33.5%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bicara Therapeutics, Inc. has a market value of $560.3M and an enterprise value of $118.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$185.4M.
Diluted earnings per share, trailing twelve months: −$3.10.
Free cash flow in the twelve months to 30 June 2026: −$135.2M.
Bicara Therapeutics, Inc. employs 103 people.
Data provided by Twelve Data
BCAX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BCAX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Bicara Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BCAX
What is the BCAX stock price forecast for 2026-2027?
The median 12-month analyst price target for Bicara Therapeutics, Inc. is $35, with estimates ranging from $8 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BCAX stock a buy right now?
Of the 14 analysts covering Bicara Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bicara Therapeutics, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BCAX?
As at 21 Nov 2026, Bicara Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (57 of 100).
Will BCAX stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts is $35, and Ticker Nerd's factor model ranks Bicara Therapeutics, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BCAX stock forecast for 2030?
No analyst covering Bicara Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $43 over the next 12 months.
How has BCAX stock performed over the past year?
Bicara Therapeutics, Inc. returned -47.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bicara Therapeutics, Inc. do?
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is designed to combine EGFR targeting with TGF-β modulation, aiming to concentrate activity within the tumor microenvironment while limiting broader systemic effects.
About Bicara Therapeutics, Inc.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is designed to combine EGFR targeting with TGF-β modulation, aiming to concentrate activity within the tumor microenvironment while limiting broader systemic effects. The company’s platform is built around dual-action biologics intended to pair precise tumor targeting with localized immune and signaling modulation. Bicara Therapeutics Inc. is centered on oncology, with current development efforts directed toward multiple solid tumor indications, including head and neck squamous cell carcinoma. Through this approach, the company plays a role in advancing next-generation cancer biologics that seek to address difficult-to-treat tumors using a more integrated therapeutic design.
CEO Dr. Claire Mazumdar Clemon M.B.A., Ph.D. · 103 employees · United States · https://www.bicara.com